Face/off: phase-specific modeling of lineage plasticity using near-patient models in genitourinary cancers
Year: 2026
Type: review
Abstract: Lineage plasticity has emerged as a fundamental mechanism of adaptive therapy resistance in prostate and bladder cancers, enabling malignant cells to bypass lineage-restricted dependencies through non-genetic reprogramming. However, plasticity is often studied as a terminal phenotype rather than as a dynamic process that unfolds over time. The endpoint-centered view can obscure the early and potentially reversible events that initiate identity loss, as well as the intermediate states through which resistant phenotypes emerge. In this review, we propose a phse-based framework for modeling lineage plasticity in genitourinary cancers. We conceptualize plasticity as a temporally ordered trajectory comprising three phases: priming, transition, and stabilization. We examine how commonly used near-patient experimental and computational platforms, including patient-derived organoids (PDOs), patient-derived xenografts (PDXs), genetically engineered mouse models (GEMMs), and artificial intelligence-based approaches, tend to sample different portions of this trajectory. By mapping these model systems to the phases, they are best equipped to simulate, we demonstrate how a phase-aware approach can resolve long-standing discrepancies in the literature and clarify the gene-regulatory logic underlying tumor identity shifts. Ultimately, this framework provides a roadmap for integrating cross-platform insights to identify critical "windows of vulnerability," informing novel strategies for the early therapeutic interception of lineage-driven resistance before it reaches a terminal, irreversible state.
Source: Gene
Institutions: Yale University, Yale Cancer Center
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,300
Awards: Graduate Research Fellowship Program (GRFP), Deciphering the Impact of ZNF397-deficiency in Promoting TET2-driven Epigenetic Rewiring, Lineage Plasticity, and Therapy Resistance in Prostate Cancer, G5606218612, Unveiling the Role of UBE2J1 as the E2 Ubiquitin Conjugating Enzyme in Androgen Receptor Degradation, Elucidating the Molecular Role of SYNCRIP in Prostate Cancer and AR Targeted Therapy Resistance
OpenAlex ID: W7167264532
